Abstract: Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.

Abstract: A disclosed system quantifies the power distribution of a wireless signal within a constrained environment using non-sequential ray tracing. For each ray, one or more ray-reflecting surface is prescreened to identify collision-eligible surfaces and identify a collision surface from the collision-eligible surfaces, wherein the collision surface is the first ray-reflecting surface that a ray collides with. A power distribution component, indicating the position and power of a ray at a particular elevation within the environment, is added to a cumulative power distribution. If a reflected ray corresponding to each collision is calculated and satisfies ray eligibility conditions, a collision surface may be determined for the reflected ray. Collision surfaces may be identified by evaluating a target function for a number of ray positions, where the target function evaluates to zero when displacement between the ray and the ray-reflecting surface is zero.

Abstract: A system generates and displays a clinical metric based on continuously collected patient physiological data, wherein the clinical metric provides a predictive measure of the likelihood of the onset of a cardiorespiratory deterioration event in the patient in a predetermined time period in the future. If the clinical metric has a configured relationship with a predetermined threshold value, embodiments may generate an alarm in addition to or instead of displaying the clinical metric. The clinical metric thus allows clinical staff to take medically indicated actions to prevent or reduce the effects of the predicted deterioration.

Abstract: Embodiments of the disclosure concern compositions and methods for genetic engineering related to hypermethylation of sequences. In particular embodiments, there are methods and compositions to induce DNA methylation in a manner that leads to transcriptional suppression of a target gene that allows characterization of the gene and/or its expression.

Abstract: One aspect of the invention provides a phantom including a confined fluidic path defining a plurality of regions of monotonically decreasing, discrete cross-sectional dimensions with respect to an imaging plane. Another aspect of the invention provides a method of assessing imaging. The method includes: placing a phantom as described herein within an imaging system; flowing one or more fluids through the phantom; and capturing one or more images of the phantom. Another aspect of the invention provides a kit for assessing imaging. The kit includes a phantom as described herein and instructions for use.

Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

Abstract: One aspect of the invention provides a mobile clinic including: an intermodal container defining at least a first opening and a second opening; a partition wall located within the intermodal container, the partition wall separating the intermodal container into an anteroom and a treatment room; and an access control device programmed to prevent passage from the anteroom into the treatment room until a user's donning of personal protective equipment is verified. Another aspect of the invention provides a collapsible structure including: a rigid base; a rigid roof; one or more collapsible walls extending between the floor and the base; and an erector system comprising four cross-bars. Another aspect of the invention provides a crate including: a bottom panel; a top panel; and a plurality of walls, wherein at least two of said plurality of wails including one or more conduits.

Abstract: The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.

Abstract: The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.

Abstract: The disclosure provides a system and method for a programmable medical wire that can be preprogrammed, and controlled and reshaped upon command. The system can include a power supply, a controller, and a multilayered wire assembly. The wire assembly includes a core conductor, actuator conductors coupled to the core conductor, selective conductors formed adjacent the core conductor and the actuator conductors, and a protective biocompatible shield around the layers. The selective conductors can be energized to activate the actuator conductors and cause the actuator conductors to bend or twist in a preprogrammed manner. By selectively controlling the direction of movement of the actuator conductors, the wire assembly can be remotely guided through body passageways to the target. Auxiliary equipment such as sensors, micro cameras, detectors, cutters, and other equipment can also be coupled to the wire assembly, and controlled and communicated with through one or more of the selective conductors.

Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).

Abstract: Wireless treatment of arrhythmias. At least some of the example embodiments are methods including: charging a capacitor of a first microchip device abutting heart tissue, the charging by harvesting ambient energy; charging a capacitor of a second microchip device abutting the heart tissue, the charging of the capacitor of the second microchip device by harvesting ambient energy; sending a command wirelessly from a communication device outside the rib cage to the microchip devices; applying electrical energy to the heart tissue by the first microchip device responsive to the command, the electrical energy applied from the capacitor of the first microchip device; and applying electrical energy to the heart tissue by the second microchip device responsive to the command to the second microchip device, the electrical energy applied from the capacitor of the second microchip device.

Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.

Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.

Abstract: Embodiments of the disclosure concern methods and compositions that relate to increasing or decreasing the weight (including, for example, by increasing or decreasing the adipose mass) in individuals in need thereof. Such methods and compositions, in particular embodiments, concern providing an effective amount of the hormone asprosin to increase adipose mass in an individual with insufficient adipose mass and providing an antibody or inhibitor of asprosin in an individual with obesity or diabetes, for example, to reduce adipose mass.

Abstract: The present disclosure concerns hyperthermic devices for treating vascular involvements related to cancer therapies, such as surgery. In specific embodiments, the device is configured to provide therapeutic heating to destroy vessel-encasing tumors while still protecting the vessel itself. In particular embodiments, the devices utilize two opposing semi-cylindrical shells that encase the vessel in need of treatment of a tumor thereon. In other devices, a flexible substrate is guided under and around the vessel and tumor thereon.

Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (Il-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.

Abstract: Embodiments of the disclosure encompass methods of amplifying nucleic acid from one or more cells using MALBAC (multiple annealing and looping-based amplification cycles) primers. In particular embodiments, the nucleic acid is amplified as amplicons in a linear manner. Specific embodiments include the removal or effective destruction of nonlinearly produced amplicons.

Abstract: Embodiments are directed to compositions and methods for treating viral infections.

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV 16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.